Peter Charlton

5.7k citations

74 papers · 4.5k indexed · h-index 34

Impact in

Oncology top 1%
- Drug Transport and Resistance Mechanisms
- Cancer-related Molecular Pathways
- PARP inhibition in cancer therapy
Toxicology top 1%

Papers in

Toxicology 7
- Bioactive Compounds and Antitumor Agents 7
Hematology 12
- Blood Coagulation and Thrombosis Mechanisms 11

Co-authors: Prakash Mistry John R. Pollard Philip M. Reaper Richard Callaghan Catherine Martin G. Berridge Julian M.C. Golec Wendy Dangerfield
Journals: Anti-Cancer Drugs (8 papers)Bioorganic & Medicinal Chemistry Letters (5 papers)British Journal of Cancer (4 papers)The Journal of Antibiotics (3 papers)Journal of Medicinal Chemistry (3 papers)
Partner nations: United Kingdom United States New Zealand

In The Last Decade

Peter Charlton

73 papers receiving 4.4k citations

Peers

Countries citing papers authored by Peter Charlton

Since Specialization

Citations

This map shows the geographic impact of Peter Charlton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Charlton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Charlton more than expected).

Fields of papers citing papers by Peter Charlton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Charlton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Charlton. The network helps show where Peter Charlton may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Charlton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Charlton Line = papers co-authored together Peter Charlton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities Cell Reports ·Kumar Sanjiv, Anna Hagenkort, José Manuel Calderón‐Montaño, Tobias Koolmeister, Philip M. Reaper, Oliver Mortusewicz, Sylvain A. Jacques, Raoul Kuiper, Niklas Schultz, Martin Scobie, Peter Charlton, John R. Pollard, Ulrika Warpman Berglund, Mikael Altun, Thomas Helleday	2015	112
2	Structure of human Bloom's syndrome helicase in complex with ADP and duplex DNA Acta Crystallographica Section D Biological Crystallography ·M.K. Swan, Valérie Legris, Adam Tanner, Philip M. Reaper, Sarah Vial, Rebecca Bordas, John R. Pollard, Peter Charlton, Julian M.C. Golec, J. A. Bertrand	2014	58
3	Crystal Structure of the Pseudomonas aeruginosa MurG: UDP-GlcNAc Substrate Complex Protein and Peptide Letters ·Kieron Brown, Sarah Vial, Neesha Dedi, James Westcott, S.W. Scally, Timothy D. H. Bugg, Peter Charlton, G.M.T. Cheetham	2013	16
4	The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy Cancer Biology & Therapy ·Remko Prevo, Emmanouil Fokas, Philip M. Reaper, Peter Charlton, John R. Pollard, W. Gillies McKenna, Ruth J. Muschel, Thomas Brunner	2012	191
5	Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation Cell Death and Disease ·Emmanouil Fokas, Remko Prevo, John R. Pollard, Philip M. Reaper, Peter Charlton, Bart Cornelissen, Katherine A. Vallis, Ester M. Hammond, Monica M. Olcina, W. Gillies McKenna, Ruth J. Muschel, Thomas Brunner	2012	278
6	Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR Nature Chemical Biology ·Philip M. Reaper, Matthew R. Griffiths, Joanna Long, Jean‐Damien Charrier, Somhairle MacCormick, Peter Charlton, Julian M.C. Golec, John R. Pollard	2011	476
7	Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis # Hepatology ·Rafal P. Witek, Christy R. Stone, Gamze Karaca, Wing‐Kin Syn, Thiago A. Pereira, Kolade M. Agboola, Alessia Omenetti, Youngmi Jung, Vanessa Teaberry, Steve S. Choi, Cynthia D. Guy, John R. Pollard, Peter Charlton, Anna Mae Diehl	2009	203
8	Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases Cancer Chemotherapy and Pharmacology ·Andrew G. Jobson, Elaine Willmore, Michael J. Tilby, Prakash Mistry, Peter Charlton, Caroline A. Austin	2008	14
9	Phenazine-1-carboxamides: Structure–cytotoxicity relationships for 9-substituents and changes in the H-bonding pattern of the cationic side chain Bioorganic & Medicinal Chemistry ·Swarna A. Gamage, Gordon W. Rewcastle, Bruce C. Baguley, Peter Charlton, William A. Denny	2005	15
10	XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro Anti-Cancer Drugs ·Teresa Brooks, Shouming W. Wang, Nils Brünner, Peter Charlton	2004	25
11	Plasminogen Activator Inhibitor-1 Supports IL-8-Mediated Neutrophil Transendothelial Migration by Inhibition of the Constitutive Shedding of Endothelial IL-8/Heparan Sulfate/Syndecan-1 Complexes The Journal of Immunology ·Lindsay J. Marshall, L. S. P. Ramdin, Teresa Brooks, Peter Charlton, Janis K. Shute	2003	6
12	Studies on Quinazolinones as Dual Inhibitors of Pgp and MRP1 in Multidrug Resistance Bioorganic & Medicinal Chemistry Letters ·Shouming Wang, Hamish Ryder, Ian Pretswell, Paul Depledge, John Milton, Timothy C. Hancox, Ian L. Dale, Wendy Dangerfield, Peter Charlton, Richard Faint, Rory Dodd, Stephanie Hassan	2002	32
13	Polymerization of Plasminogen Activator Inhibitor-1 Journal of Biological Chemistry ·Aiwu Zhou, Richard Faint, Peter Charlton, Timothy R. Dafforn, Robin W. Carrell, David A. Lomas	2001	52
14	Ex vivo activity of XR5000 against solid tumors Anti-Cancer Drugs ·Michael H. Neale, Peter Charlton, Ian A. Cree	2000	7
15	An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2,1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells Biochemical Pharmacology ·Kay Padget, Alistair Stewart, Peter Charlton, Michael J. Tilby, Caroline A. Austin	2000	30
16	Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro Clinical & Experimental Metastasis ·Teresa Brooks, Jennita Slomp, Paul H.A. Quax, A.C.W. de Bart, Marilyn T. Spencer, Jan H. Verheijen, Peter Charlton	2000	35
17	In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance British Journal of Cancer ·Prakash Mistry, Jane A. Plumb, Sue Eccles, Sue‐Ann Watson, IL Dale, Hamish Ryder, G. Box, Peter Charlton, David J. Templeton, P Bevan	1999	17
18	Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative British Journal of Cancer ·IL Dale, W Tuffley, Richard Callaghan, J. A. Holmes, Karen H. Martin, M Luscombe, Prakash Mistry, Hamish Ryder, Alistair Stewart, Peter Charlton, PR Twentyman, P Bevan	1998	43
19	Novel Drimane Sesquiterpene Esters from Aspergillus ustus var. pseudodeflectus with Endothelin Receptor Binding Activity. The Journal of Antibiotics ·Martin A. Hayes, Stephen K. Wrigley, I. CHETLAND, Elwood E. Reynolds, A. Martyn Ainsworth, D.V. Renno, Mohammed Abdul Latif, Xue‐Min Cheng, Donald Hupe, Peter Charlton, Annette M. Doherty	1996	37
20	The selectivity of action of the aspartic-proteinase inhibitor IA3 from yeast (Saccharomyces cerevisiae) Biochemical Journal ·Thomas Dreyer, Martin J. Valler, John Kay, Peter Charlton, Ben M. Dunn	1985	26

About Peter Charlton

Peter Charlton is a scholar working on Toxicology, Hematology, Cancer Research, Oncology and Molecular Biology, having authored 74 papers that have together received 4.5k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (23 papers), DNA Repair Mechanisms (13 papers), Protease and Inhibitor Mechanisms (13 papers), Blood Coagulation and Thrombosis Mechanisms (11 papers), Drug Transport and Resistance Mechanisms (10 papers), Bioactive Compounds and Antitumor Agents (7 papers), Cancer-related Molecular Pathways (6 papers) and Cell death mechanisms and regulation (6 papers). The work is most often cited by research in Oncology (2.1k citations), Toxicology (198 citations), Cancer Research (628 citations), Molecular Biology (2.7k citations) and Hematology (277 citations). Peter Charlton has collaborated with scholars based in United Kingdom, United States and New Zealand. Frequent co-authors include Prakash Mistry, John R. Pollard, Philip M. Reaper, Richard Callaghan, Catherine Martin, G. Berridge, Julian M.C. Golec, Wendy Dangerfield, Alistair Stewart and Jean‐Damien Charrier. Their work appears in journals such as Anti-Cancer Drugs, Bioorganic & Medicinal Chemistry Letters, British Journal of Cancer, The Journal of Antibiotics and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact